MERTK and metabolic dysfunction-associated steatohepatitis: In a preclinical NASH model, treatment with the selective Axl inhibitor bemcentinib reduces NASH-associated fibrosis and concomitantly increases Gas6, suggesting a compensatory mechanism of hepatoprotective MerTK activation [121,133].